Literature DB >> 22057632

How do MYBPC3 mutations cause hypertrophic cardiomyopathy?

Steven Marston1, O'Neal Copeland, Katja Gehmlich, Saskia Schlossarek, Lucie Carrier, Lucie Carrrier.   

Abstract

It is well established that MYBPC3 mutations are the most common cause of hypertrophic cardiomyopathy, accounting for about half of identified mutations. However, when compared with mutations in other myofibrillar proteins that cause hypertrophic cardiomyopathy, MYBPC3 mutations seem to be the odd one out. The most striking characteristic of HCM mutations in MYBPC3 is that many are within introns and are predicted to cause aberrant splicing leading to a frameshift and a premature chain termination, yet the truncated peptides have never been identified in human heart tissue carrying these mutations. Instead of expression of a poison peptide we consistently observe haploinsufficiency of MyBP-C in MYBPC3 mutant human heart muscle. In this review we investigate the mechanism for MyBP-C haploinsufficiency and consider how this haploinsufficiency could cause hypertrophic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057632     DOI: 10.1007/s10974-011-9268-3

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  35 in total

Review 1.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics.

Authors:  Lynne E Maquat
Journal:  Nat Rev Mol Cell Biol       Date:  2004-02       Impact factor: 94.444

2.  Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein.

Authors:  W Rottbauer; M Gautel; J Zehelein; S Labeit; W M Franz; C Fischer; B Vollrath; G Mall; R Dietz; W Kübler; H A Katus
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

3.  Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.

Authors:  Pascale Richard; Philippe Charron; Lucie Carrier; Céline Ledeuil; Theary Cheav; Claire Pichereau; Abdelaziz Benaiche; Richard Isnard; Olivier Dubourg; Marc Burban; Jean-Pierre Gueffet; Alain Millaire; Michel Desnos; Ketty Schwartz; Bernard Hainque; Michel Komajda
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

Review 4.  How do mutations in contractile proteins cause the primary familial cardiomyopathies?

Authors:  Steven B Marston
Journal:  J Cardiovasc Transl Res       Date:  2011-03-22       Impact factor: 4.132

5.  Protein kinase A-induced myofilament desensitization to Ca(2+) as a result of phosphorylation of cardiac myosin-binding protein C.

Authors:  Peter P Chen; Jitandrakumar R Patel; Inna N Rybakova; Jeffery W Walker; Richard L Moss
Journal:  J Gen Physiol       Date:  2010-12       Impact factor: 4.086

6.  Cardiac myosin-binding protein-C phosphorylation and cardiac function.

Authors:  Sakthivel Sadayappan; James Gulick; Hanna Osinska; Lisa A Martin; Harvey S Hahn; Gerald W Dorn; Raisa Klevitsky; Christine E Seidman; Jonathan G Seidman; Jeffrey Robbins
Journal:  Circ Res       Date:  2005-10-13       Impact factor: 17.367

7.  A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy.

Authors:  Kathryn M Meurs; Ximena Sanchez; Ryan M David; Neil E Bowles; Jeffrey A Towbin; Peter J Reiser; Judith A Kittleson; Marcia J Munro; Keith Dryburgh; Kristin A Macdonald; Mark D Kittleson
Journal:  Hum Mol Genet       Date:  2005-10-19       Impact factor: 6.150

8.  Cardiac myosin binding protein C phosphorylation is cardioprotective.

Authors:  Sakthivel Sadayappan; Hanna Osinska; Raisa Klevitsky; John N Lorenz; Michelle Sargent; Jeffrey D Molkentin; Christine E Seidman; Jonathan G Seidman; Jeffrey Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

9.  Normal passive viscoelasticity but abnormal myofibrillar force generation in human hypertrophic cardiomyopathy.

Authors:  Anita C Hoskins; Adam Jacques; Sonya C Bardswell; William J McKenna; Victor Tsang; Cristobal G dos Remedios; Elisabeth Ehler; Kim Adams; Shapour Jalilzadeh; Metin Avkiran; Hugh Watkins; Charles Redwood; Steven B Marston; Jonathan C Kentish
Journal:  J Mol Cell Cardiol       Date:  2010-07-06       Impact factor: 5.000

10.  Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy.

Authors:  G Bonne; L Carrier; J Bercovici; C Cruaud; P Richard; B Hainque; M Gautel; S Labeit; M James; J Beckmann; J Weissenbach; H P Vosberg; M Fiszman; M Komajda; K Schwartz
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

View more
  50 in total

Review 1.  Structure, interactions and function of the N-terminus of cardiac myosin binding protein C (MyBP-C): who does what, with what, and to whom?

Authors:  Mark Pfuhl; Mathias Gautel
Journal:  J Muscle Res Cell Motil       Date:  2012-04-20       Impact factor: 2.698

2.  Introducing a series of topical special issues of the Journal of Muscle Research and Cell Motility: MYBPC3 special issue editorial.

Authors:  Steven B Marston; Mathias Gautel
Journal:  J Muscle Res Cell Motil       Date:  2012-05       Impact factor: 2.698

Review 3.  MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction.

Authors:  Verena Behrens-Gawlik; Giulia Mearini; Christina Gedicke-Hornung; Pascale Richard; Lucie Carrier
Journal:  Pflugers Arch       Date:  2013-12-12       Impact factor: 3.657

Review 4.  Targeting the sarcomere to correct muscle function.

Authors:  Peter M Hwang; Brian D Sykes
Journal:  Nat Rev Drug Discov       Date:  2015-04-17       Impact factor: 84.694

5.  An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy.

Authors:  Poornima Gajendrarao; Navaneethakrishnan Krishnamoorthy; Senthil Selvaraj; Francesca Girolami; Franco Cecchi; Iacopo Olivotto; Magdi Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2015-05-14       Impact factor: 4.132

Review 6.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

7.  Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.

Authors:  Andre Monteiro da Rocha; Guadalupe Guerrero-Serna; Adam Helms; Carly Luzod; Sergey Mironov; Mark Russell; José Jalife; Sharlene M Day; Gary D Smith; Todd J Herron
Journal:  J Mol Cell Cardiol       Date:  2016-09-10       Impact factor: 5.000

8.  Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.

Authors:  David Barefield; Mohit Kumar; Pieter P de Tombe; Sakthivel Sadayappan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-24       Impact factor: 4.733

9.  CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs.

Authors:  Mohammad A Mandegar; Nathaniel Huebsch; Ekaterina B Frolov; Edward Shin; Annie Truong; Michael P Olvera; Amanda H Chan; Yuichiro Miyaoka; Kristin Holmes; C Ian Spencer; Luke M Judge; David E Gordon; Tilde V Eskildsen; Jacqueline E Villalta; Max A Horlbeck; Luke A Gilbert; Nevan J Krogan; Søren P Sheikh; Jonathan S Weissman; Lei S Qi; Po-Lin So; Bruce R Conklin
Journal:  Cell Stem Cell       Date:  2016-03-10       Impact factor: 24.633

10.  MYBPC3 Haplotype Linked to Hypertrophic Cardiomyopathy in Rhesus Macaques (Macaca mulatta).

Authors:  Robert F Oldt; Kimberly J Bussey; Matthew L Settles; Joseph N Fass; Jeffrey A Roberts; J Rachel Reader; Srivathsan Komandoor; Victor A Abrich; Sreetharan Kanthaswamy
Journal:  Comp Med       Date:  2020-08-04       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.